|
Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for
Phase III Medical Device Study and Joins OmniComm’s CRO Preferred Program
Fort Lauderdale, FL, August 18, 2009 -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM.OB ), a leader in integrated
electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a
Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III
trial investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and
will recruit up to 300 patients over the course of two years. Amarex also joins OmniComm’s CRO Preferred
Program, which will allow them to offer OmniComm’s flexible, robust electronic data capture solution, TrialMasterTM,
to their clients. Amarex also benefits from the CRO Program’s distinct advantages that include fixed pricing with no
hidden fees, complete sales and marketing support, and dedicated hosting services in OmniComm’s world class
hosting facility.
"We are honored that such a well-reputed CRO like Amarex has joined our CRO Preferred Program and look
forward to working closely with them on this high profile study," remarked Stephen Johnson, COO of OmniComm
Systems. "Amarex has a reputation for delivering superior service to their customers- a commitment that we share
here at OmniComm. The combination of our products and services will be beneficial for both companies, but more
importantly will offer our customers the solutions they need to bring life saving drugs and devices to market."
About Amarex Clinical Research
Amarex Clinical Research, Inc. is a global clinical research organization supplying a full range of clinical trial
services to the pharmaceutical, biotech, and medical device communities. Amarex has managed studies in a
breadth of therapeutic areas in Phase I through Phase IV study development. The company employs approximately
50 personnel in its offices located in the United States, and reaches clients worldwide through its Internet-based
data collection and reporting capabilities. Amarex is headquartered in Germantown, MD. For more information,
please visit the company’s Web site at http://www.amarexcro.com.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical,
biotechnology, research and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver
products and services that ensure ease of use, faster study build, ease of integration and better performance.
OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale
institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has
U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in
New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the
sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand.
As a result, actual results may differ materially from any financial outlooks stated herein. Further information on
potential factors that could affect the Company's financial results can be found in the Company's Reports on Form
10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
